Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H30NO3.Br |
Molecular Weight | 412.361 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CC(C)[N@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3
InChI
InChIKey=LHLMOSXCXGLMMN-WDTICOSOSA-M
InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17+,18+,19?,21?;
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68009241
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68009241
Ipratropium (ipratropium bromide, ATROVENT® HFA) is a muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Ipratropium (ipratropium bromide, ATROVENT® HFA) is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca2+ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.
CNS Activity
Sources: https://books.google.ru/books?id=ZyGsBAAAQBAJ&dq
Curator's Comment: Raeburn, David, Giembycz, Mark A. (2012). Rhinitis: Immunopathology and Pharmacotherapy. Springer. p. 133:
"Topical intranasal ipratropium bromide has limited central nervous system penetration".
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL216 |
0.49 nM [Ki] | ||
Target ID: CHEMBL211 |
1.5 nM [Ki] | ||
Target ID: CHEMBL245 |
0.51 nM [Ki] | ||
Target ID: CHEMBL1821 |
0.66 nM [Ki] | ||
Target ID: CHEMBL2035 |
1.7 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ATROVENT HFA Approved UseATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Launch Date2004 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.5 pg/mL |
20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL |
IPRATROPIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
31.7 pg/mL |
20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL |
IPRATROPIUM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
35.4 pg/mL |
20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL |
IPRATROPIUM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.04 pg × h/mL |
20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL |
IPRATROPIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
123 pg × h/mL |
20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL |
IPRATROPIUM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
131 pg × h/mL |
20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL |
IPRATROPIUM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h |
20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL |
IPRATROPIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
95.5% |
20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL |
IPRATROPIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: |
unhealthy, 18 - 75 years n = 96 Health Status: unhealthy Condition: perennial allergic rhinitis Age Group: 18 - 75 years Sex: M+F Population Size: 96 Sources: |
Disc. AE: Nasal disorder NOS, Nasal dryness... AEs leading to discontinuation/dose reduction: Nasal disorder NOS (17%) Sources: Nasal dryness (2%) Epistaxis (2%) |
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: |
unhealthy, 2 - 5 years n = 43 Health Status: unhealthy Condition: common colds Age Group: 2 - 5 years Sex: M+F Population Size: 43 Sources: |
Disc. AE: Epistaxis... AEs leading to discontinuation/dose reduction: Epistaxis (1 patient) Sources: |
84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: |
unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: |
Disc. AE: Epistaxis, Upper respiratory tract infection... AEs leading to discontinuation/dose reduction: Epistaxis (1 patient) Sources: Upper respiratory tract infection (1 patient) Ear infection (1 patient) Exacerbation of asthma (1 patient) |
200 ug single, respiratory Highest studied dose Dose: 200 ug Route: respiratory Route: single Dose: 200 ug Sources: |
unhealthy, mean 40.7 years n = 20 Health Status: unhealthy Condition: stable chronic asthma Age Group: mean 40.7 years Sex: M+F Population Size: 20 Sources: |
Disc. AE: Nausea and vomiting... AEs leading to discontinuation/dose reduction: Nausea and vomiting (1 patient) Sources: |
42 ug 1 times / day steady, respiratory Recommended Dose: 42 ug, 1 times / day Route: respiratory Route: steady Dose: 42 ug, 1 times / day Sources: |
unhealthy, mean 42.6 years n = 99 Health Status: unhealthy Condition: rhinorrhea Age Group: mean 42.6 years Sex: M+F Population Size: 99 Sources: |
Other AEs: Nasal disorder NOS... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nasal disorder NOS | 17% Disc. AE |
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: |
unhealthy, 18 - 75 years n = 96 Health Status: unhealthy Condition: perennial allergic rhinitis Age Group: 18 - 75 years Sex: M+F Population Size: 96 Sources: |
Epistaxis | 2% Disc. AE |
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: |
unhealthy, 18 - 75 years n = 96 Health Status: unhealthy Condition: perennial allergic rhinitis Age Group: 18 - 75 years Sex: M+F Population Size: 96 Sources: |
Nasal dryness | 2% Disc. AE |
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: |
unhealthy, 18 - 75 years n = 96 Health Status: unhealthy Condition: perennial allergic rhinitis Age Group: 18 - 75 years Sex: M+F Population Size: 96 Sources: |
Epistaxis | 1 patient Disc. AE |
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: |
unhealthy, 2 - 5 years n = 43 Health Status: unhealthy Condition: common colds Age Group: 2 - 5 years Sex: M+F Population Size: 43 Sources: |
Ear infection | 1 patient Disc. AE |
84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: |
unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: |
Epistaxis | 1 patient Disc. AE |
84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: |
unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: |
Exacerbation of asthma | 1 patient Disc. AE |
84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: |
unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: |
Upper respiratory tract infection | 1 patient Disc. AE |
84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: |
unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: |
Nausea and vomiting | 1 patient Disc. AE |
200 ug single, respiratory Highest studied dose Dose: 200 ug Route: respiratory Route: single Dose: 200 ug Sources: |
unhealthy, mean 40.7 years n = 20 Health Status: unhealthy Condition: stable chronic asthma Age Group: mean 40.7 years Sex: M+F Population Size: 20 Sources: |
Nasal disorder NOS | 19 patients | 42 ug 1 times / day steady, respiratory Recommended Dose: 42 ug, 1 times / day Route: respiratory Route: steady Dose: 42 ug, 1 times / day Sources: |
unhealthy, mean 42.6 years n = 99 Health Status: unhealthy Condition: rhinorrhea Age Group: mean 42.6 years Sex: M+F Population Size: 99 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21 |
yes [IC50 17.4 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21 |
yes [IC50 2.5 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21 |
yes [IC50 3.6 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21 |
yes [IC50 30.5 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21 |
yes [IC50 62.8 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21 |
strong | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21 |
strong | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21 |
strong | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21 |
strong | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21 |
strong | |||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. | 2001 |
|
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? | 2001 |
|
Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. | 2001 Apr |
|
The role of domiciliary nebulizers in managing patients with severe COPD. | 2001 Apr |
|
Tiotropium bromide. | 2001 Apr |
|
Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. | 2001 Jan |
|
Analyses of quaternary ammonium drugs in horse urine by capillary electrophoresis-mass spectrometry. | 2001 Jul |
|
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. | 2001 Jun |
|
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Salbutamol and ipratropium in COPD. | 2001 Mar |
|
Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. | 2001 May |
|
Effects of inhalation of albuterol sulphate, ipratroprium bromide and frusemide on breathing mechanics and gas exchange in healthy exercising horses. | 2001 May |
|
Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. | 2001 Oct |
|
Posttraumatic pseudo-cerebrospinal fluid rhinorrhea. | 2001 Sep |
|
[Effect of anticholinergic therapy on myocardial reserve dynamics in patients with chronic obstructive bronchitis]. | 2001 Sep-Dec |
|
[Pharmacodynamics of inhalation broncholytic agents introduced in a single dose by nebulizer in patients with severe exacerbation of bronchial asthma]. | 2002 |
|
Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. | 2002 |
|
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. | 2002 Apr |
|
Clinical review: severe asthma. | 2002 Feb |
|
Mydriasis due to self-administered inhaled ipratropium bromide. | 2002 Mar |
Sample Use Guides
The usual starting dose of ATROVENT® HFA is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7952627
Ba 679 BR, atropine, and ipratropium bromide inhibited electrical field stimulation (EFS)-induced contraction with IC50 values of 0.17, 0.74, and 0.58 nM, respectively, in guinea pig trachea. Ba 679 BR had a slower onset and longer duration of action than atropine or ipratropium bromide (the times required to attain 50% of the maximum response were 34.8, 3.8, and 7.6 min, respectively, and the times required for 50% recovery of the response were 540, 31.6, and 81.2 min, respectively).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R01AX03
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
||
|
WHO-ATC |
R03BB01
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C170538
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | |||
|
22254-24-6
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | |||
|
DTXSID60858923
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | |||
|
3263
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | |||
|
SUB40135
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | |||
|
46659
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | |||
|
DB00332
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | |||
|
VJV4X1P2Z1
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | |||
|
1445143
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB08276MIG
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | |||
|
m6387
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
244-873-8
Created by
admin on Fri Dec 15 18:45:55 GMT 2023 , Edited by admin on Fri Dec 15 18:45:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD